LY3475766 - IV + LY3475766 - SC + Placebo - IV + Placebo - SC

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Dyslipidemias

Conditions

Dyslipidemias

Trial Timeline

Sep 3, 2019 → Mar 31, 2021

NCT ID

NCT04052594

About LY3475766 - IV + LY3475766 - SC + Placebo - IV + Placebo - SC

LY3475766 - IV + LY3475766 - SC + Placebo - IV + Placebo - SC is a phase 1 stage product being developed by Eli Lilly for Dyslipidemias. The current trial status is completed. This product is registered under clinical trial identifier NCT04052594. Target conditions include Dyslipidemias.

What happened to similar drugs?

6 of 6 similar drugs in Dyslipidemias were approved

Approved (6) Terminated (0) Active (0)

✅Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mgYuhanApproved

✅Atorvastatin + AtorvastatinPfizerApproved

✅AtorvastatinPfizerApproved

✅Atorvastatin + Atorvastatin + AtorvastatinPfizerApproved

✅AtorvastatinPfizerApproved

✅Atorvastatin + Atorvastatin + AtorvastatinPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04052594	Phase 1	Completed	Sep 3, 2019	Mar 31, 2021	Dyslipidemias

Competing Products

15 competing products in Dyslipidemias

See all competitors

Product	Company	Stage	Hype Score
LY3202328 + Placebo + Atorvastatin + Simvastatin	Eli Lilly	Phase 1	29
Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mg	Yuhan	Approved	43
LY3885125 + Placebo	Eli Lilly	Phase 1	21
LY3561774 + Placebo	Eli Lilly	Phase 1	29
LY3561774 + Placebo	Eli Lilly	Phase 2	35
LY2484595 + Placebo + Atorvastatin	Eli Lilly	Phase 2	35
Atorvastatin + Atorvastatin	Pfizer	Approved	43
Atorvastatin	Pfizer	Approved	43
Atorvastatin + Atorvastatin + Atorvastatin	Pfizer	Approved	43
Vupanorsen + Placebo	Pfizer	Phase 2	35
Atorvastatin	Pfizer	Approved	43
Atorvastatin + Atorvastatin + Atorvastatin	Pfizer	Approved	43
GWP42003 + GWP42003 + GWP42004 + Placebo	Jazz Pharmaceuticals	Phase 2	32
ARO-APOC3	Arrowhead Pharmaceuticals	Phase 2	32
ARO-ANG3 + sterile normal saline (0.9% NaCl)	Arrowhead Pharmaceuticals	Phase 1	26